Impel Pharmaceuticals To Present At The JMP Securities Life Sciences Conference
Impel Pharmaceuticals (NASDAQ: IMPL) announced that CEO Adrian Adams will present a company overview at the JMP Securities Life Sciences Conference on June 15, 2022, at 2:00 p.m. ET in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Impel Pharmaceuticals (NASDAQ: IMPL) announced that CEO Adrian Adams will present a company overview at the JMP Securities Life Sciences Conference on June 15, 2022, at 2:00 p.m. ET in New York. The event will focus on the company’s development of transformative therapies targeting high unmet medical needs, particularly in the central nervous system. A live webcast will be available on their Investors page, with a replay accessible for 90 days. Impel’s notable product is Trudhesa, a nasal spray for migraine treatment.
Details
News Market Reaction – IMPL
The recorded move for IMPL in the trading session of this news was -2.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, June 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 2:00 p.m. ET in New York, New York.
A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the presentation will be available on the website for 90 days.
About Impel Pharmaceuticals
Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary POD® technology with well-established therapeutics. In addition to Trudhesa® nasal spray, which is approved in the U.S. for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism.
For additional information about Impel, please visit www.ImpelPharma.com
Contact:
Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com
Investor Relations
Christina Tartaglia
Stern Investor Relations
Phone: 212-362-1200
Email: christina.tartaglia@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.